Emerging Lessons From COVID-19 for the US Clinical Research Enterprise

Angus et al discuss the study of Janiaud et al in which they present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10722 patients from...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2021-03, Vol.325 (12), p.1159
Main Authors: Angus, Derek C, Gordon, Anthony C, Bauchner, Howard
Format: Article
Language:English
Subjects:
Clinical trials
Coronaviruses
COVID-19
Health care
Health services
Mechanical ventilation
Patients
Placebos
Systematic review
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angus et al discuss the study of Janiaud et al in which they present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10722 patients from 6 RCTs (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality or with benefit for other clinical outcomes, including length of hospital stay, mechanical ventilation use, and clinical improvement or deterioration. The rapid development and deployment of vaccines is surely the single greatest achievement. Despite initial concerns that the health care system would be overwhelmed, the clinical community rallied and provided care to hundreds of thousands of critically ill patients.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2021.3284